title: Targeted diphtheria toxin to treat BPDCN.
abstract: In this issue of Blood, Frankel et al describe a novel treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN) using an engineered version of diphtheria toxin that is targeted to malignant cells via a fusion with interleukin (IL)3 (see panel A).
authors.affiliation: NATIONAL INSTITUTES OF HEALTH.
authors.forename: David J
authors.initials: DJ
authors.lastname: FitzGerald
mesh_terms: D003713:Dendritic Cells / Q000473:pathology*; D019337:Hematologic Neoplasms / Q000473:pathology* / Q000628:therapy*; D006801:Humans; D008297:Male; D016185:Receptors, Interleukin-3 / Q000037:antagonists & inhibitors*; D011993:Recombinant Fusion Proteins / Q000627:therapeutic use*; D012878:Skin Neoplasms / Q000473:pathology* / Q000628:therapy*
chemical_list: D016185:Receptors, Interleukin-3; D011993:Recombinant Fusion Proteins; C000592123:tagraxofusp